Article Text

Download PDFPDF

Successful use of valciclovir in a case of recurrent urticaria associated with genital herpes
  1. A Khunda,
  2. M Kawsar,
  3. J M Parkin,
  4. G E Forster
  1. Infection and Immunity Clinical Group, Barts and The London NHS Trust, London E1 1BB, UK
  1. Correspondence:
 Dr A Khunda, Ambrose King Centre, Royal London Hospital, Whitechapel, London E1 1BB, UK;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Urticaria is a common skin condition but the symptoms and signs can be extremely distressing. The condition is often idiopathic.1 The management of urticaria can be frustrating even when triggers are identified.2 We describe a case of recurrent urticaria associated with genital herpes attacks and a successful use of suppressive therapy with valaciclovir.

A 35 year old white woman presented in March 2000 to a genitourinary medicine (GUM) clinic with 5 year history of recurrent lesions typical of genital herpes simplex virus (HSV) infection occurring almost every month. She had also been developing physical urticaria manifesting as itchy weals on pressure areas of the body, approximately 24 hours before the onset of genital HSV attacks. The lesions showed no characteristics of erythema multiforme or vasculitis. Each urticarial attack lasted from 20–30 minutes and had a cholinergic element being exacerbated by exercise and heat. Antihistamines were not effective. She had contact sensitivity to perfumes, make up, and coloured bath products. There was no history of angioedema, other atopic disease, or drug allergies. She was otherwise well and on no medication.

Culture for HSV was negative. However, serology was positive for HSV type 1 IgG antibody. HSV type 2, hepatitis B and C serology were negative. Her IgE level was normal. Immunological investigations including CD4/CD8 count showed no evidence of immunodeficiency.

Her HSV attacks were frequent and distressing. She began suppressive therapy with valciclovir 500 mg twice a day and antihistamines in March 2000 and the symptoms were well controlled. Both urticaria and herpes recurred when the valciclovir therapy was discontinued after 6 months. She recommenced her therapy in October 2000 but required higher doses of valciclovir to control her symptoms. She is currently taking valaciclovir 1 g twice daily and cetirizine 10 mg daily. She had a single episode of urticaria associated with genital herpes precipitated by intense sunlight exposure in September 2001 and had no further attacks since then.

Urticaria can be triggered by a large number of diverse allergens including sexually transmitted infections such as hepatitis B virus.3 A case of chronic urticaria preceding genital herpes and a successful treatment with a short course of aciclovir has been described. However, the long term follow up of this patient was not known.4 A recent study in Ohio has reported a successful use of maintenance therapy with aciclovir in five out of 12 patients with chronic urticaria; none had genital herpes.5 In our patient, control of both genital herpes and recurrent urticaria with valciclovir therapy suggests a close temporal association between the onset of urticaria and development of herpetic lesions. The exact role of HSV in the pathogenesis of urticaria is unknown but it may be related to hypersensitivity reaction to viral antigens. Antiviral agents may be effective by suppressing these antigens.

This case demonstrates the importance of early recognition of urticaria associated with HSV infections in order to avoid delay in instituting antiviral treatment in GUM clinics or other settings for this disabling skin condition.